PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-46.40%
Negative revenue growth while TSM stands at 2.40%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-61.49%
Negative gross profit growth while TSM is at 4.29%. Joel Greenblatt would examine cost competitiveness or demand decline.
-408.27%
Negative EBIT growth while TSM is at 5.18%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-408.27%
Negative operating income growth while TSM is at 5.18%. Joel Greenblatt would press for urgent turnaround measures.
-339.14%
Negative net income growth while TSM stands at 6.92%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-346.43%
Negative EPS growth while TSM is at 6.78%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-342.86%
Negative diluted EPS growth while TSM is at 6.78%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.13%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-3.67%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-146.15%
Negative OCF growth while TSM is at 32.89%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
4.83%
FCF growth under 50% of TSM's 31.94%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
214.06%
10Y revenue/share CAGR at 50-75% of TSM's 305.71%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
-8.16%
Negative 5Y CAGR while TSM stands at 41.16%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-21.22%
Negative 3Y CAGR while TSM stands at 752.09%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-413.82%
Negative 10Y OCF/share CAGR while TSM stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-1784.49%
Negative 5Y OCF/share CAGR while TSM is at 34.12%. Joel Greenblatt would question the firm’s operational model or cost structure.
-109.14%
Negative 3Y OCF/share CAGR while TSM stands at 10.27%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-947.67%
Negative 10Y net income/share CAGR while TSM is at 328.13%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-650.66%
Negative 5Y net income/share CAGR while TSM is 46.86%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-256.25%
Negative 3Y CAGR while TSM is 22.37%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
1510.75%
10Y equity/share CAGR above 1.5x TSM's 230.01%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
105.29%
5Y equity/share CAGR above 1.5x TSM's 25.01%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
70.43%
3Y equity/share CAGR above 1.5x TSM's 1.99%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-47.61%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
2.64%
Inventory shrinking or stable vs. TSM's 9.06%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
-8.17%
Negative asset growth while TSM invests at 9.74%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-2.61%
We have a declining book value while TSM shows 11.39%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-0.27%
Our R&D shrinks while TSM invests at 5.90%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-4.33%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.